BN Business News
Add your company to Business Communicator →

Business · 21/09/2016Updated: 10/17/2026 · 1 min read

FDA Suspends Approval of Chloramphenicol Capsules Due to Safety Concerns

Summary

The FDA has suspended the approval of an abbreviated new drug application for chloramphenicol capsules, 250 milligrams, held by Armenpharm, Ltd., and determined that other products containing chloramphenicol were withdrawn from sale due to safety or effectiveness concerns.

Original source language: Federal Register — Food and Drug AdministrationOpen original release →

Explore insights

Business insights →